Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment

Francesco Nucera,Paolo Ruggeri,Calogera Claudia Spagnolo,Mariacarmela Santarpia,Antonio Ieni,Francesco Monaco,Giovanni Tuccari,Giovanni Pioggia,Sebastiano Gangemi

DOI: https://doi.org/10.3390/ijms25126685

IF: 5.6

2024-06-19

International Journal of Molecular Sciences

Abstract:Lung cancer (LC) is one of the most prevalent cancers in both men and women and today is still characterized by high mortality and lethality. Several biomarkers have been identified for evaluating the prognosis of non-small cell lung cancer (NSCLC) patients and selecting the most effective therapeutic strategy for these patients. The introduction of innovative targeted therapies and immunotherapy with immune checkpoint inhibitors (ICIs) for the treatment of NSCLC both in advanced stages and, more recently, also in early stages, has revolutionized and significantly improved the therapeutic scenario for these patients. Promising evidence has also been shown by analyzing both micro-RNAs (miRNAs) and the lung/gut microbiota. MiRNAs belong to the large family of non-coding RNAs and play a role in the modulation of several key mechanisms in cells such as proliferation, differentiation, inflammation, and apoptosis. On the other hand, the microbiota (a group of several microorganisms found in human orgasms such as the gut and lungs and mainly composed by bacteria) plays a key role in the modulation of inflammation and, in particular, in the immune response. Some data have shown that the microbiota and the related microbiome can modulate miRNAs expression and vice versa by regulating several intracellular signaling pathways that are known to play a role in the pathogenesis of lung cancer. This evidence suggests that this axis is key to predicting the prognosis and effectiveness of ICIs in NSCLC treatment and could represent a new target in the treatment of NSCLC. In this review, we highlight the most recent evidence and data regarding the role of both miRNAs and the lung/gut microbiome in the prediction of prognosis and response to ICI treatment, focusing on the link between miRNAs and the microbiome. A new potential interaction based on the underlying modulated intracellular signaling pathways is also shown.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the roles of microRNAs (miRNAs) and microbiota in the pathogenesis of non - small - cell lung cancer (NSCLC), as well as their potential roles in predicting the response to immune checkpoint inhibitor (ICI) treatment. Specifically, the paper focuses on the following aspects:

1. **The role of miRNAs**: The paper analyzes in detail how miRNAs participate in the tumor - suppression and carcinogenesis processes of NSCLC by regulating key signaling pathways, such as the RB pathway, the PI3K pathway, the RTK/RAS/MAPK pathway, the Wnt pathway and the TGF - β pathway. These miRNAs play important roles in tumor growth, angiogenesis, immune escape, etc.

2. **The role of microbiota**: The paper explores the roles of the lung and gut microbiota in the pathogenesis of NSCLC. The microbiota affects the development of NSCLC by regulating the inflammatory state and immune response. In particular, the dysbiosis of the microbiota may lead to chronic inflammation, which in turn promotes tumorigenesis and development.

3. **The interaction between miRNAs and microbiota**: The paper also studies the interaction between miRNAs and microbiota and its impact on the pathogenesis of NSCLC. For example, certain bacteria can increase the adhesion and migration abilities of NSCLC cells by activating the TLR4 and MAPK/ERK1 - 2 signaling pathways. Meanwhile, specific miRNAs (such as miRNA - 148a and miRNA - 223) can be regulated by certain probiotics (such as bifidobacteria and lactobacilli), thereby inhibiting tumor growth.

4. **Predicting the ICI treatment response**: The paper further explores the potential value of miRNAs and microbiota in predicting the ICI treatment response. By analyzing these biomarkers, patients suitable for ICI treatment can be selected more precisely, improving the treatment effect.

In summary, this paper aims to comprehensively analyze the roles of miRNAs and microbiota in the pathogenesis of NSCLC and explore their potential as biomarkers for predicting the ICI treatment response. This helps to better understand the complex pathophysiological processes of NSCLC and provides new ideas for future treatment strategies.